The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.
about
Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.A novel dual-cytokine-antibody fusion protein for the treatment of CD38-positive malignanciesCalcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cellsTrogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma
P2860
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The Human CD38 Monoclonal Anti ...... Chronic Lymphocytic Leukemia.
@en
type
label
The Human CD38 Monoclonal Anti ...... Chronic Lymphocytic Leukemia.
@en
prefLabel
The Human CD38 Monoclonal Anti ...... Chronic Lymphocytic Leukemia.
@en
P2093
P2860
P50
P1476
The Human CD38 Monoclonal Anti ...... n Chronic Lymphocytic Leukemia
@en
P2093
Adrian Wiestner
Alba Matas-Céspedes
Anna Vidal-Crespo
Armando López-Guillermo
Elías Campo
Jeroen Lammerts van Bueren
Neus Villamor
Parul Doshi
Patricia Pérez-Galán
P2860
P304
P356
10.1158/1078-0432.CCR-15-2095
P407
P577
2016-09-16T00:00:00Z